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Abstract
Colorectal cancer (CRC) is the second most common cancer in women and the third most
common cancer in men globally. The identification of differentially expressed genes associ-
ated to patient’s clinical data may represent a useful approach to find important genes in
CRC carcinogenesis. Previously, the TULP3 transcription factor was identified as a possible
prognostic biomarker in pancreatic ductal adenocarcinoma. Considering that pancreatic
and colorectal tissues have the same embryonic origin, we investigated the profile of TULP3
expression in CRC hypothesizing that it may have a role in its development. We compara-
tively analysed TULP3 gene expression in CRC and normal adjacent colonic tissue and
assessed association of expression profiles with survival and clinicopathological informa-
tion, using publicly available datasets. TULP3 expression levels were increased in CRC
when compared to the adjacent non-tumoral tissue. In addition, higher TULP3 gene expres-
sion was associated to lymphatic and vascular invasion in colon adenocarcinoma (COAD)
and rectum adenocarcinoma (READ), respectively. In summary, our results point to a possi-
ble role of TULP3 as a diagnostic and prognostic biomarker in CRC. Additional studies are
necessary to confirm these preliminary findings.
Introduction
The global impact of cancer incidence and mortality is increasing, according to the Interna-
tional Agency for Research on Cancer (IARC). In 2020, more than 17 million new cancer cases
will be diagnosed and about 10 million deaths in both sexes will be related to cancer [1].
Among all types of cancer, gastrointestinal (GI) tumors (those affecting the esophagus, pan-
creas, stomach and intestines) are responsible for approximately 20% of all diagnosed cancers
worldwide and about 15% of cancer-related deaths [2].
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Colorectal cancer (CRC) encompasses tumours affecting the colon and rectum. CRC is
globally recognized as the third most commonly diagnosed type of cancer in men (746,000
cases, 10.0% of all cancer cases) and the second in women (614,000 cases, 9.2% of all cancer
cases). Although mortality is considered low (694,000 deaths, 8.5% of total cancer deaths), less
developed regions present higher mortality rates, as well as unfavorable survival for individuals
diagnosed with CRC [1].
mRNA expression is recognized to play an important role in tumour cell survival and
tumour progression, and comparative gene expression profiles between tumours and adjacent
tissues has been important in the identification of biomarkers. [3]. Thus, in colorectal and
adjacent non-tumoral tissues, analysis of differential gene expression, coupled with analysis of
patient’s clinical data may represent a useful approach to identify important genes in CRC car-
cinogenesis [3, 4]. In a previous study based on computational analyses, Sartor et al. [5], identi-
fied the Tubby-like Protein 3 (TULP3) transcription factor as a master regulator of
carcinogenesis in pancreatic ductal adenocarcinoma (PDAC) from microarray-based expres-
sion profiles. Additionally, the authors observed higher TULP3 expression associated to a poor
prognosis in PDAC patients. Given the similarity in embryonic development of pancreatic
and intestinal tissues [6–10], we hypothesized that TULP3 may also play a role in colorectal
carcinogenesis.
Methods
Data acquisition and preprocessing
Gene expression data from patient biopsies and control samples were obtained from The Can-
cer Genome Atlas–TCGA Research Network (http://cancergenome.nih.gov) and Gene Expres-
sion Omnibus (GEO) [11] databases. From TCGA, we analysed the COAD and READ studies
(Colon Adenocarcinoma and Rectum Adenocarcinoma, respectively) [12]. GEO datasets were
downloaded under accession numbers GSE21510 [13] and GSE24514 [14]. The description of
the selected datasets, including sample size, is presented in S1 Table. All data were downloaded
in June 2018. Raw expression data from GSE21510 (GPL570) and GSE24514 (GPL96) studies
were normalised using the RMA method implemented in the affy Bioconductor R package [15]
see S1A and S1B Fig. Harmonized data (hg38 alignment) of RNA-Seq raw counts from the
selected TCGA studies (IlluminaHiSeq) were downloaded and preprocessed using the TCGA-
biolinks Bioconductor R package [16]. The GC-content method was used to normalise the data
and quantile filtering was adopted to avoid biased gene expression values [16] (see S1C and
S1D Fig). After the normalisation and filtering processes, we log-transformed the data to com-
pare TULP3 gene expression between tumoral and adjacent non-tumoral tissues (NT). Princi-
pal component analysis was performed in each study to filter possibly biased samples (see S2
Fig).
Statistical analyses
Data normality assumptions were verified in all studies and the statistical tests chosen to com-
pare TULP3 levels were: two-tailed Mann-Whitney-Wilcoxon test (for GSE21510, COAD, and
READ studies), and two tailed t test (for GSE24514 study).
Survival analysis was performed in COAD and READ studies using survival Bioconductor R
package [17]. To compare the prognostic value of TULP3 gene expression, we used the median
to dichotomize the cohort. Kaplan-Meier method was used to estimate survival curves and
log-rank test was used to compare the overall survival among groups. Hazard Ratios (HR) with
95% confidence intervals were calculated and P values from likelihood ratio tests were
considered.
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To measure the association between the dichotomized TULP3 gene expression and clinico-
pathological information from COAD and READ studies, we performed Pearson’s Chi-
squared test (with Yates’ continuity correction), or Fisher exact test. All data preprocessing
and analyses were performed in R 3.4.2 statistical software.
Results
Bioinformatics analysis of TULP3 gene expression
We comparatively analysed TULP3 gene expression in GSE21510, GSE24514, COAD, and
READ studies. The TULP3 gene expression comparison between tumoral and NT samples
showed significant statistical difference in all studies, with P = 5.00e-06, P = 6.43e-03,
P = 2.20e-16 and P = 2.13e-04, respectively (Fig 1A–1D). In the TCGA COAD and READ
studies, we observed higher fold-changes of TULP3 gene expression in tumour samples relative
to NT samples (logFC = 0.804 and logFC = 0.590, respectively). Additionally, TULP3 expres-
sion profile from GSE21501 study was not able to differentiate primary CRC from metastatic
(see S3 Fig).
Survival analysis
In order to verify the prognostic value of TULP3 gene expression, we performed survival anal-
ysis using the TCGA COAD and READ datasets, since this information was readily available.
We used the median to dichotomize groups classified as high and low gene expression (nor-
malised and quantile-filtered data without log-transformation). Using this approach, no sur-
vival difference was found in patients diagnosed with COAD and READ (see S4 Fig). In order
to verify whether pathologic staging (pTNM) correlates to survival, we performed Kaplan-
Meier curves according to pTNM classification in COAD and READ studies. We observed
that there is a difference between the early stages (I and II) versus advanced stages (III and IV).
Patients diagnosed in the early stages of the disease presented better prognosis when compared
to more advanced stages (see S5 Fig). The survival analysis of staging (I, II, III and IV) of
COAD and READ is depicted in S6 Fig. In READ study, the Cox proportional hazards regres-
sion analysis did not converge, therefore there is no estimates of P values, neither HR. Addi-
tionally, we performed survival curves based on TULP3 gene expression and pTNM
classification, to analyse the association between these variables in COAD and READ studies.
To increase the sample size, we analysed early (I and II) and advanced stages (III and IV). We
used the median of TULP3 to dichotomize the groups in low and high expression. No survival
difference in TULP3 gene expression was observed in patients with early and advanced stages
(see S7 and S8 Figs).
Association of gene expression and clinical data
Chi-squared analysis was performed to verify the association among dichotomized TULP3
gene expression and the clinical variables: gender, pathologic primary tumour extension (pT),
pathologic lymph node involvement (pN), pathologic distant metastasis (pM), pathologic stage
(pTNM), residual tumour, history of colon polyps, lymphatic invasion, vascular invasion, can-
cer status and hypermutated status. As observed in the results presented in Table 1, significant
association was found in lymphatic invasion (COAD) and vascular invasion (READ), in which
a higher TULP3 expression was associated to lymphatic invasion in COAD-TCGA and to vas-
cular invasion in READ-TCGA.
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Discussion
TULP3 belongs to a family of proteins that possess a tubby domain in C-terminal, which
exhibits a conserved nuclear localization and allows it to act as a transcription factor [18]. In a
study of mammalian development [19], the authors have demonstrated the important role of
Tulp3 gene since its expression is ubiquitous throughout embryonic mice development and
knockout of Tulp3 leads to neural tube defects and embryonic lethality.
The Tulp3 protein negatively regulates the Hedgehog pathway in the absence of Sonic
Hedgehog (Shh) ligand in mouse embryo at primary cilium (a microtubule-based membrane
Fig 1. TULP3 gene expression comparison between groups. (A) GSE21510, (B) GSE24514, (C) COAD-TCGA, and (D) READ-TCGA. (NT) Adjacent non-tumoral
tissue. (CRC) Colorectal cancer. (COAD) Colon adenocarcinoma. (READ) Rectum adenocarcinoma. (logFC) Log fold-change. Median is represented as a solid black
line, whereas mean is represented as a black square.
https://doi.org/10.1371/journal.pone.0210762.g001
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extension that acts as sensory signaling compartment) [20, 21]. Tulp3 is also implicated in vesi-
cle trafficking [20, 22], since the tubby domain binds to PIP2 (phosphatidylinositol 4,5-bispho-
sphate), a component of cell membranes [23]. Mukhopadhyay et al. (2010) [22] highlighted
the role of Tulp3 and intraflagellar transport complex A (IFT-A) in trafficking of a subset of G
protein-coupled receptors (GPCRs) to cilia, in mouse embryo. Also, Santagata et al. (2001)
Table 1. Association of dichotomized TULP3 gene expression with clinical variables of individuals diagnosed with COAD and READ.











Female 119 (53.60) 103 (46.40) 0.142† 33 (44.00) 42 (56.00) 0.238†
Male 117 (46.43) 135 (53.57) 49 (54.44) 41 (45.56)
pT
T1 or T2 25 (51.02) 24 (48.98) 1.000† 12 (60.00) 8 (40.00) 1.000†
T3 or T4 72 (51.80) 67 (48.20) 29 (59.18) 20 (40.82)
pN
N0 68 (53.97) 58 (46.03) 1.000† 27 (60.00) 18 (40.00) 0.676†
N+ 43 (53.75) 37 (46.25) 15 (53.27) 13 (46.73)
pM
M0 97 (56.72) 74 (43.28) 0.317† 36 (58.06) 26 (41.94) 1.000�
M1 15 (45.45) 18 (54.55) 6 (54.54) 5 (45.46)
pTNM
Stage I or II 65 (54.17) 55 (45.83) 1.000† 25 (58.14) 18 (41.86) 0.995†
Stage III or IV 46 (54.12) 39 (45.88) 16 (55.17) 13 (44.83)
Residual tumour
R0 94 (53.71) 81 (46.29) 0.614† 35 (57.38) 26 (42.62) 1.000�
R1 or R2 10 (45.45) 12 (54.55) 6 (54.54) 5 (45.46)
History of colon polyps
NO 55 (57.89) 40 (42.11) 0.371† 33 (61.11) 21 (38.89) 0.440†
YES 51 (50.50) 50 (49.50) 9 (47.37) 10 (52.63)
Lymphatic invasion
NO 40 (44.94) 49 (55.06) 0.024† 16 (53.33) 14 (46.67) 0.661†
YES 63 (62.38) 38 (37.62) 24 (61.54) 15 (38.46)
Vascular invasion
NO 63 (49.22) 65 (50.78) 0.195† 21 (45.65) 25 (54.35) 0.029†
YES 29 (61.70) 18 (38.30) 15 (78.95) 4 (21.05)
Cancer status
Tumor free 19 (48.72) 20 (51.28) 0.589† 1 (50.00) 1 (50.00) 1.000�
With tumor 92 (55.09) 75 (44.91) 41 (57.75) 30 (42.25)
Hypermutated status
NO 66 (52.80) 59 (72.20) 0.640† 37 (56.92) 28 (43.08) 1.000�
YES 19 (59.37) 13 (40.63) 2 (66.67) 1 (33.33)
Age mean (min-max) 67.6 (31.2–90.0) 66.2 (31.2–90.0)
(pT) Pathologic primary tumour extension. (pN) Pathologic lymph nodes involvement. (pM) Pathologic distant metastasis. (pTNM) Pathologic stage. Significant data
are emphasized in bold.
† Pearson Chi-squared test.
� Fisher exact test.
https://doi.org/10.1371/journal.pone.0210762.t001
TULP3: A potential biomarker in colorectal cancer?
PLOS ONE | https://doi.org/10.1371/journal.pone.0210762 January 14, 2019 5 / 10
[23] suggested that Tulp3 may play a role in GPCR signaling and gene expression regulation in
Neuro-2A cell.
Several studies describe the important role of Tulp3 in embryo development however, few
studies have been carried out investigating its possible role in carcinogenesis. Recently, Qian
et al. [24] used radiogenomics analysis to identify genes associated with risk prediction in glio-
blastoma multiforme and TULP3 was involved. In another study, using an in silico approach,
increased TULP3 gene expression was associated with poor prognosis in PDAC patients, but
these results were not yet validated in clinical samples [5].
We explored the profile of TULP3 gene expression in four independent datasets related to
colorectal tissues. In all of them, we observed a statistically significant increase in TULP3
expression levels in colorectal samples compared to NT samples, despite the small number
compared to tumour samples. To classify the NT specimens, some criteria must be followed,
for example, NT tissue collection should be more than 2cm away from the resected lesion mar-
gin and should not contain tumour cells in histopathological analysis [25] and, sometimes, no
adjacent non-tumoral tissue is available for collection. However, even with this issue is worthy
to study differences in NT and tumours samples. Recent works that used TCGA and GEO
publicly available datasets also found relevant results despite the difference in sample sizes
[26–28]. Taking together, these results indicate a possible role of TULP3 in the diagnosis of
CRC, however, additional studies are needed to confirm these preliminary findings. Another
point to consider is that using only tumour and adjacent non-tumoral tissue we possibly
added bias caused by not analysing true normal samples. Although histologically NT samples
are usually considered to be normal, they could present gene expression alterations [29].
Availability of survival and clinicopathological information in the TCGA datasets allowed
us to investigate the prognostic impact of TULP3 gene expression in COAD and READ
patients. Although no association of TULP3 expression profiles and survival was identified,
higher levels of TULP3 were associated with vascular and lymphatic invasion in our study. The
histological identification of lymphatic and vascular invasion has long been recognized as a
potential prognostic indicator and predictor of patient outcome [30, 31]. Some studies
reported that lymphatic invasion is associated with an increased risk of regional lymph node
metastases [32–34] and vascular invasion with risk of distant metastases [35].
The clinicopathological characteristics, especially the tumour-node-metastasis (TNM) stag-
ing and lymphovascular invasion, are related to CRC prognostic factors. Recently, molecular
markers are gaining more attention as predictive of a worse outcome, an example are the
members of Wnt signaling pathway, which are known to play and important role in CRC pro-
gression [36, 37]. A molecular marker associated to tumour invasion is the β-catenin, which
plays key roles in the Wnt/β-catenin signaling pathway, as well as in cellular junctions with E-
cadherin. The disruption of adherens junctions is implicated in epithelial-to-mesenchymal
transition (EMT) alterations, which in turn may promotes tumour spreading and, conse-
quently, metastasis. The Wnt/β-catenin signaling pathway is also related to initiation and pro-
gression of CRC [37, 38]. A recent study, identified Tulp3 as a direct target of canonical β-
catenin signaling in cerebral cortex of mice [39]. Taken together, these observations led us to
hypothesize that the association found in our study between TULP3 gene expression and, lym-
phatic and vascular invasion may be due to an increased activity of the β-catenin pathway.
Another point to consider is that CRC is a heterogeneous and complex disease, and many
studies classify both colon and rectum tumours as a common entity [40]. Evidences suggest
that grouping these anatomically distinct diseases could be a clinical and biological oversimpli-
fication, therefore it would be important to study colon and rectum cancers as separated dis-
eases, which includes differentiating them at the molecular level [40].
TULP3: A potential biomarker in colorectal cancer?
PLOS ONE | https://doi.org/10.1371/journal.pone.0210762 January 14, 2019 6 / 10
Conclusions
To the best of our knowledge, this preliminary study is the first one to describe increased
TULP3 gene expression in CRC compared to adjacent non-tumoral tissue, and to associate
increased gene expression to vascular and lymphatic invasion in CRC. These results point to a
possible role of TULP3 as a diagnostic and prognostic biomarker in colorectal cancer.
Supporting information
S1 Table. Description of the datasets selected to analyze TULP3 gene expression, including
the classification and sample size, and the technique employed to quantify the transcripts.
(NT) Adjacent non-tumoral tissue. (CRC) Colorectal cancer. (COAD) Colon adenocarci-
noma. (READ) Rectum adenocarcinoma.
(DOCX)
S1 Fig. Normalisation plots. (A) GSE21510. (B) GSE24514. (C) COAD-TCGA. (D) READ--
TCGA. Blue boxplots correspond to adjacent non-tumoral samples (NT) and the red ones cor-
respond to colorectal cancer (CRC) samples.
(TIFF)
S2 Fig. Principal component analysis (PCA) plots. (A) GSE21510. (B) GSE24514. (C)
COAD-TCGA. (D) READ-TCGA. (PC) Principal component. (NT) Adjacent non-tumoral
tissue. (CRC) Colorectal cancer. (COAD) Colon adenocarcinoma. (READ) Rectum adenocar-
cinoma.
(TIFF)
S3 Fig. TULP3 gene expression comparison between groups of GSE21501. TULP3 expres-
sion profile from GSE21501 study. (NT) Adjacent non-tumoral tissue. (CRC) Colorectal can-
cer. Median is represented as a solid line. Equal letters above the boxplots indicate no
statistical difference among the groups. We performed Kruskal-Wallis test followed by Benja-
mini-Hochberg correction for multiple comparisons.
(TIFF)
S4 Fig. Survival probabilities in TCGA studies. We used the median to dichotomize the
groups classified as high and low gene expression (normalised and quantile-filtered data with-
out log-transformation). (A) Comparison of TULP3 gene expression in Colon adenocarci-
noma (COAD). (B) Comparison of TULP3 gene expression in Rectum adenocarcinoma
(READ). The x-axis corresponds to overall survival in months. (HR) Hazard ratio.
(TIFF)
S5 Fig. Survival probabilities of early and advanced stages in TCGA studies. We grouped
patients classified in stages I and II as early stage and, patients classified in stages III and IV as
advanced stage. (A) Comparison of survival between early versus advanced stages in Colon
adenocarcinoma (COAD). (B) Comparison of survival between early versus advanced stages
in Rectum adenocarcinoma (READ). The x-axis corresponds to overall survival in months.
(HR) Hazard ratio.
(RAR)
S6 Fig. Survival probabilities of pathologic staging (pTNM) in TCGA studies. (A) Compar-
ison of survival among pNTM stages in Colon adenocarcinoma (COAD). (B) Comparison of
survival among pNTM stages in Rectum adenocarcinoma (READ). The x-axis corresponds to
overall survival in months. (HR) Hazard ratio. In READ study the Cox proportional hazards
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regression analysis did not converged, therefore there is no estimates of P values neither HR.
(RAR)
S7 Fig. Survival probabilities of TULP3 gene expression in early and advanced stages in
COAD-TCGA study. We used the median of TULP3 to dichotomize the groups in low and
high expression for early and advanced stages. (A) Comparison of survival between early stages
(I and II). (B) Comparison of survival between advanced stages (III and IV). The x-axis corre-
sponds to overall survival in months. (HR) Hazard ratio.
(RAR)
S8 Fig. Survival probabilities of TULP3 gene expression in early and advanced stages in
READ-TCGA study. We used the median of TULP3 to dichotomize the groups in low and
high expression for early and advanced stages. (A) Comparison of survival between early stages
(I and II). (B) Comparison of survival between advanced stages (III and IV). The x-axis corre-
sponds to overall survival in months. (HR) Hazard ratio.
(RAR)
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